SAB3500346
抗-ACE2 兔抗
affinity isolated antibody, buffered aqueous solution
别名:
抗-ACE2
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA (i), IF, IHC, WB
Citations:
6
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
mouse, human
technique(s)
immunofluorescence: suitable, immunohistochemistry: suitable, indirect ELISA: suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... ACE2(59272)
General description
血管紧张素转换酶2（ACE2）是一种膜相关和分泌的酶，由定位于人类染色体Xp22.2的基因编码。Ace 2是ACE的人类同源物，主要在心脏、肾脏和睾丸的血管内皮上表达。Ace2结构包含N端PD和C端Collectrin样结构域（CLD）。
Immunogen
ACE2抗体是针对对应于人ACE2中心周围氨基酸的合成肽产生的。
Biochem/physiol Actions
血管紧张素转化酶2（ACE2）催化Ang I向Ang1-9的转化。它还可能参与维持心脏和肾脏局部肾素-血管紧张素系统（RAS）的平衡。Ace 2充当严重急性呼吸综合征-冠状病毒（SARS-CoV）和新型冠状病毒（SARS-CoV-2）的刺突糖蛋白的功能性受体，SARS-CoV-2是2019冠状病毒病（COVID-19）的致病因子。Ace 2表达下调导致心血管疾病。
Features and Benefits
完放心地使用我们的抗体。如果抗体在您的申请的研究中不起作用，我们将全额退款或安排替代抗体。了解更多信息。
Physical form
以含有0.02%叠氮化钠的PBS形式提供。
Other Notes
可以使用阻断肽SBP3500346阻断该抗体的作用。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
低风险生物材料
此项目有
Lin Wang et al.
Theranostics, 11(2), 649-664 (2021-01-05)
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide epidemic of the lethal respiratory coronavirus disease (COVID-19), necessitating urgent development of specific and effective therapeutic tools. Among several therapeutic targets of coronaviruses, the spike protein is
Clara Husser et al.
Microorganisms, 12(3) (2024-03-28)
While having already killed more than 7 million of people worldwide in 4 years, SARS-CoV-2, the etiological agent of COVID-19, is still circulating and evolving. Understanding the pathogenesis of the virus is of capital importance. It was shown that in
Shine Varghese Jancy et al.
Biological procedures online, 25(1), 22-22 (2023-07-27)
The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the host cell is mediated through the binding of the SARS-CoV-2 Spike protein via the receptor binding domain (RBD) to human angiotensin-converting enzyme 2 (hACE2). Identifying compounds that inhibit
Elisa Avolio et al.
Clinical science (London, England : 1979), 135(24), 2667-2689 (2021-11-23)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a broad range of clinical responses including prominent microvascular damage. The capacity of SARS-CoV-2 to infect vascular cells is still debated. Additionally, the SARS-CoV-2 Spike (S) protein may act as a
Lai-Keng Loi et al.
Heliyon, 9(12), e22614-e22614 (2023-12-18)
The entry of SARS-CoV-2 into host cells involves the interaction between the viral spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Given that the spike protein evolves rapidly to evade host immunity, therapeutics that block ACE2 accessibility, such
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持